BioSpace News Archive

Softhread Inc. is pleased to announce an agreement with Clinical Consultants International (CCI), a wholly-owned subsidiary of Novo Integrated Sciences Inc., to offer a zero trust cybersecurity solution for smart and interconnected healthcare services consolidating its entrance into the rapidly evolving Health Care 4.0 ecosystem for health care delivery.

Aziyo Biologics, Inc., a regenerative medicine company with a portfolio of commercial therapies, announced the appointment of David Colpman to its Board of Directors and audit committee, effective October 20, 2022.

PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the Company is invited at upcoming Jefferies 2022 London Healthcare Conference.

Seal Rock Therapeutics, Inc., a clinical stage company developing first-in-class and best-in-class kinase inhibitors, today announced oral and poster presentations at The Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD), taking place November 4-8, 2022, in Washington, DC.

Ardelyx, Inc. (Nasdaq: ARDX) today announced that post-hoc analyses from its Phase 3 T3MPO trials will be presented in two posters at the 2022 American College of Gastroenterology Annual Scientific Meeting (ACG 2022) taking place in Charlotte, North Carolina from October 21-26, 2022 and virtually.

Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, today announced it will report financial results for the third quarter 2022 after the market closes on Monday, November 7, 2022.

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, announced that it has elected to file a voluntary petition under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware.

Bausch Health Companies Inc. and its gastroenterology business, Salix Pharmaceuticals today announced four posters and one abstract featuring data for XIFAXAN (rifaximin), TRULANCE (plecanatide) and RELISTOR (methylnaltrexone bromide) that are being presented at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting.

Invivoscribe is pleased to announce that they have filed a supplemental Pre-Market Approval (sPMA) submission with the U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) for the use of the LeukoStrat® CDx FLT3 Mutation Assay as the companion diagnostic for Daiichi Sankyo’s investigational drug quizartinib.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented data detailing the baseline characteristics of patients with Parkinson’s disease (PD) in the Opicapone Treatment Initiation Open-Label Study (OPTI-ON).